Antitumor agent-145 产品活性：Antitumor agent-145 (Compound Ir5) 是一种肿瘤抑制剂，具有显著荧光和线粒体靶向性，其激发波长是 405 nm，通过诱导 necroptosis 以及激活程序性坏死相关的免疫反应发挥抗癌作用。 产品来源： https://www.medchemexpress.cn/antitumor-agent-145.html 研究领域：Apoptosis 作用靶点：Necroptosis In Vitro: Antitumor agent-145 (Compound Ir5) (48 h) could effectively reduce the cell viability of BEL-7402/DDP cells with IC50 value of 0.49 μM and a resistance coefficient (RF) of 1.04. No obvious cytotoxicity Antitumor agent-145. In Vivo: Antitumor agent-145 (Compound Ir5) (1.5 or 3.0 mg/kg, intravenous injection, every other day for 21 days) significantly reduced tumor volume and inhibited tumor metastasis in BALB/c mice. Antitumor agent-145 does not cause significant liver and kidney dysfunction in mouse models. Antitumor agent-145 (1.5 or 3.0 mg/kg, intravenous injection, every other day for 21 days) BEL-7402/DDP tumor xenograft models can significantly inhibit the growth and metastasis of CDDP resistant tumors without causing obvious tissue damage. 相关产品：Bardoxolone | Sulfaphenazole | RIP1/RIP3/MLKL activator 1 | Thioacetamide | Apostatin-1 | Cholesteryl hemisuccinate | Chlorhexidine (digluconate) | IM-54 | Necrostatin-7 | Duocarmycin SA | Necroptosis-IN-1 | Necrostatin-5 | Kongensin A | KWCN-41 | Necroptosis-IN-3 | (-)-Latifolin | AG311 | ALDH1A inhibitor 673A | Anticancer agent 118 | Anticancer agent 146 | Anticancer agent 178 | Antiparasitic agent-15 | Antiparasitic agent-16 | Antitumor photosensitizer-3 | Chlorhexidine (digluconate) (Standard) | Cholicamideβ | HDAC-IN-70 | HDL-16 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。